Here are four things to know:
1. The study included patients from across 83 U.K centers through the British Society for Rheumatology Biologics Register.
2. Around 27.9 percent of the 577 patients who were employed began biologic treatment at the time researchers sought out participants. At 12-month follow-up, patients receiving biologics demonstrated significantly greater improvements in overall work and activity impairment than patients who did not receive biologics.
3. Patients in both groups experienced no difference in absenteeism.
4. Researchers conducted a meta-analysis of 1,109 axSpA patients, which found biologics treatment correlated with work and activity impairment improvements. There was also no difference in absenteeism.
More articles on biologics:
Vericel appoints CMO: 3 details
17 key players in the global spine biologics market
Paragon 28 launches bone graft harvesting system for foot and ankle: 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
